Whither the modulation of platinum?
Leyland-Jones
B
B
Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892.
D004999:Amifostine / Q000494:pharmacology; D000963:Antimetabolites / Q000494:pharmacology; D019328:Buthionine Sulfoximine; D002945:Cisplatin / Q000009:adverse effects*; D004050:Ditiocarb / Q000494:pharmacology; D006801:Humans; D008717:Methionine Sulfoximine / Q000031:analogs & derivatives / Q000494:pharmacology
D000963:Antimetabolites; D008717:Methionine Sulfoximine; D019328:Buthionine Sulfoximine; D004050:Ditiocarb; D004999:Amifostine; D002945:Cisplatin